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One strategy for enhancing the establishment of probiotic bacteria in the human intestinal tract is via the parallel administration
of a prebiotic, which is referred to as a synbiotic. Here we present a novel method that allows a rational selection of putative probiotic strains to be used in synbiotic applications: in vivo selection (IVS). This method consists of isolating candidate probiotic
strains from fecal samples following enrichment with the respective prebiotic. To test the potential of IVS, we isolated bifidobacteria from human subjects who consumed increasing doses of galactooligosaccharides (GOS) for 9 weeks. A retrospective analysis of the fecal microbiota of one subject revealed an 8-fold enrichment in Bifidobacterium adolescentis strain IVS-1 during GOS
administration. The functionality of GOS to support the establishment of IVS-1 in the gastrointestinal tract was then evaluated
in rats administered the bacterial strain alone, the prebiotic alone, or the synbiotic combination. Strain-specific quantitative
real-time PCR showed that the addition of GOS increased B. adolescentis IVS-1 abundance in the distal intestine by nearly 2 logs
compared to rats receiving only the probiotic. Illumina 16S rRNA sequencing not only confirmed the increased establishment of
IVS-1 in the intestine but also revealed that the strain was able to outcompete the resident Bifidobacterium population when provided with GOS. In conclusion, this study demonstrated that IVS can be used to successfully formulate a synergistic synbiotic
that can substantially enhance the establishment and competitiveness of a putative probiotic strain in the gastrointestinal tract.

T

he mechanistic role of the gastrointestinal (GI) microbiota
and its metabolites in maintaining human health has been well
demonstrated (1–3). Gut microbes provide several important
benefits for their host, including provision of nutrients, development and maturation of the immune system, and protection
against pathogens via colonization resistance (4). However, the
gut microbiota may also contribute to obesity, inflammatory and
autoimmune diseases, and other chronic disease states (5–7). Such
diseases are often associated with compositional alterations in the
fecal microbiota, a condition referred to as “dysbiosis” (8). Given
that the presence of specific types of bacteria and their relative
abundance within the gut are considered to affect host health,
there is much interest in devising strategies that modulate gut
microbiota composition and potentially redress disease-related
dysbiotic patterns (9).
Dietary approaches currently available to modulate the gut microbiota include prebiotics (10–12), fermentable fibers (13, 14),
probiotics (or live biotherapeutics) (15), and synbiotics, which are
a combination of a probiotic and a prebiotic (11, 16). According to
Kolida and Gibson (16), synbiotics can be either complementary
or synergistic. Complementary synbiotics consist of a probiotic
and a prebiotic selected to independently confer benefits to the
host. In contrast, synergistic synbiotics are comprised of a prebiotic chosen specifically for the selected probiotic to stimulate its
growth, activity, and survival in the gastrointestinal tract (16).
Synergistic synbiotics therefore hold the potential to improve
the establishment of a specific bacterial strain when introduced
into the gastrointestinal tract. Unfortunately, successful synergistic synbiotic combinations are not well established in the literature
despite a large number of studies. To our knowledge, only two
reports describe a synbiotic combination in which the prebiotic
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significantly enhanced the stability, persistence, or metabolic activity of a specific probiotic strain in vivo (17–19). As noted by
Kolida and Gibson (16), this low success rate may be explained by
the selection of most synbiotic combinations on an arbitrary basis,
including shelf life, industrial performance, availability, and cost.
Indeed, few synbiotic preparations are formulated based on a rational selection of both the prebiotic and the probiotic (12, 16),
such as via in vitro or in vivo screens assessing the ability of the
probiotic to utilize the prebiotic (17–21). Even if synbiotic formulations were based on these criteria, synergism between the probiotic strain and the prebiotic was rarely observed in human and
animal trials (22–24). These observations suggest that the probiotic strains were unable to utilize the selected prebiotic to expand
their populations under the prevailing ecological conditions in the
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gastrointestinal tract. We therefore propose that synergistic synbiotics are likely to be more successful if selection of the probiotic
organism is based on ecological criteria.
In this report, we introduce the concept of in vivo selection
(IVS) to identify putative probiotic strains with enhanced ecological performance when used in synbiotic applications. The concept consists of isolating putative probiotic strains from fecal or
intestinal samples after enriching for them with dietary administration of the prebiotic. We reasoned that such strains would likely
be able to successfully utilize the prebiotic in vivo within the constraints of the competitive gastrointestinal environment. To test
IVS, we isolated bifidobacteria from fecal samples of human individuals who had consumed the prebiotic galactooligosaccharide
(GOS) during a previous human trial (25). A combination of approaches was used to select a candidate probiotic strain (Bifidobacterium adolescentis strain IVS-1) enriched by GOS in vivo. We
then tested the synergistic potential of this strain and GOS when
administered as a synbiotic combination in a rat model of highfat-diet-induced nonalcoholic fatty liver disease (NAFLD). A
NAFLD model without severe inflammatory disease was chosen,
as inflammation would potentially confound the ecological analysis due to its effects on gut microbiota composition. Although no
direct physiological benefits were observed in the rats, the results
from the gut microbiota analysis demonstrated that IVS can be
used to select a synergistic synbiotic combination that substantially increases the ecological performance of the bacterial strain in
vivo.
MATERIALS AND METHODS
Isolation of in vivo-enriched bifidobacteria from humans. In a previous
study (25), fecal samples were collected from subjects who consumed
cumulative doses of GOS (0, 2.5, 5, and 10 g per day for 3 weeks each).
Throughout the study, fresh fecal samples were collected and immediately
plated onto Rogosa LS agar to enumerate bifidobacteria. Bacterial counts
were used to identify GOS responders (i.e., individuals who experienced
significant increases in numbers of bifidobacteria), and colonies were
picked during the period in which 10 g GOS day⫺1 was consumed. Colonies were purified by successive liquid and plate cultures, and stock cultures were prepared and stored at ⫺80°C. A total of 28 individual colonies
(2 to 3 per subject) were propagated. To classify isolates, DNA was extracted by using the phenol-chloroform extraction method (26), and the
16S rRNA gene was amplified by using the 8F and 1391R universal primers. The amplification product was purified (QIAquick PCR purification
kit; Qiagen Inc., MD) and sequenced by a commercial provider (Eurofins
MWG Operon, Huntsville, AL). Identity was determined by comparing
sequences to sequences in the GenBank database; species were assigned
based on the best match.
In vitro growth on GOS. Each isolate was screened for its ability to use
GOS as a growth substrate in an MRS broth culture. Growth experiments
were performed with basal MRS broth containing 2% (wt/vol) glucose or
GOS (Purimune; GTC Nutrition, Golden, CO). The latter contained 92%
GOS, with residual carbohydrates being mainly lactose. Control cultures
were therefore also grown on basal MRS broth supplemented with the
same amount of lactose as that present in the commercial GOS (giving a
final concentration of 0.16% lactose). Cultures were incubated anaerobically at 37°C, and growth was determined by optical density measurement
at 600 nm. Strains that grew on GOS to cell densities similar to those on
glucose were considered GOS fermenters.
Strain-specific primer design and validation. The genome of B. adolescentis IVS-1 was sequenced to draft status by using a standard shotgun
library prep kit on a Roche GS FLX sequencer at the former Core for
Applied Genomics and Ecology (CAGE) (University of Nebraska, Lincoln, NE). Sequencing resulted in 65,460 reads that were assembled de
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novo by using the gsAssembler (Newbler) module of the GS-FLX OffInstrument software suite. This resulted in draft sequences of 148 contigs
with ⬃15-fold coverage.
Unique genes in B. adolescentis IVS-1 were identified by comparing the
annotated genome with other available B. adolescentis genomes in the JGI
database (using the Phylogenetic Profiler for Single Genes tool in IMG).
From this analysis, the clustered regularly interspaced short palindromic
repeat (CRISPR)-associated helicase Cas3 was selected as the target gene,
and a putative primer pair was designed by using Primer 3 software (27).
Candidate primers were evaluated for hairpin and dimer formation by
using Netprimer (Premier Biosoft International, Palo Alto, CA). The selected forward (F) primer TTGCTTTTGCTCTGGAACATAC and reverse
(R) primer GTAATGAGGTAATACTGCGTCC were validated in silico by
performing a BLAST search against the NCBI database. These primers
were also validated experimentally by quantitative real-time PCR (qRTPCR) using DNA from 10 different Bifidobacterium strains related to
strain IVS-1 (each having ⬎96% identity at the 16S rRNA gene level).
These strains included Bifidobacterium adolescentis ATCC 15703, Bifidobacterium adolescentis L2-32, Bifidobacterium longum subsp. longum
ATCC 15707, Bifidobacterium longum DJO10A, Bifidobacterium longum
ATCC 15697, Bifidobacterium longum subsp. longum F8, Bifidobacterium
longum subsp. longum JDM301, Bifidobacterium sp. strain 113, Bifidobacterium sp. strain 12_1_47BFAA, and Bifidobacterium sp. strain HMLN14.
Furthermore, to test if primers could select against fecal bacterial communities in both humans and rats, DNA from 23 human fecal samples and 10
Sprague-Dawley rat fecal samples from an independent study were tested.
Human fecal materials analyzed included the baseline samples (i.e.,
before GOS supplementation) from 18 subjects from a previous study
by Davis et al. (25) as well as five other human fecal samples from an
independent study.
Quantitative real-time PCR. qRT-PCR was performed by using a
Mastercycler Realplex2 instrument (Eppendorf AG, Hamburg, Germany). Each PCR was performed with 25-l volumes using real-time
master mix containing SYBR (5 Prime Inc., Gaithersburg, MD) and either
genus-specific primers for Bifidobacterium, F primer TCGCGTC(C/T)G
GTGTGAAAG and R primer CACATCCAGC(A/G)TCCAC (25, 26), or
the strain-specific primers for B. adolescentis IVS-1 (described above),
each at a concentration of 0.8 M. Annealing temperatures of 58°C and
61°C were used for the genus- and strain-specific PCRs, respectively. Standard curves for absolute quantification of bacterial cell numbers were
prepared by using cultures of B. adolescentis IVS-1 grown overnight (14
h), as described previously (25, 26).
Administration of the probiotic, prebiotic, and synbiotic to rats. A
freeze-dried powder of Bifidobacterium adolescentis IVS-1 was produced
by a contract manufacturer (Culture Systems, Mishawaka, IN). The powder contained 5 ⫻ 1010 CFU g⫺1 and was stable during the entire course of
the study. For delivery to the rats, the powder was suspended in drinking
water (double-distilled water) to reach a concentration of 3 ⫻ 107 cells
ml⫺1. GOS was diluted in water at a concentration of 0.033 g ml⫺1, and
the synbiotic was prepared by mixing both IVS-1 and GOS in the abovementioned concentrations. All preparations were prepared fresh daily in
drinking water for the duration of the experiment. Cell viability and stability were validated by plating samples on MRS medium at different time
points. This analysis revealed that IVS-1 was highly stable in drinking
water, with levels dropping ⬍1 log over 24 h. The addition of GOS did not
influence the viability of the probiotic in drinking water (data not shown).
Rat study design. Synergism of the synbiotic preparation was tested in
a rat model of NAFLD (28). Four-week-old male Sprague-Dawley rats
were obtained from Charles River Laboratories (Wilmington, MA) and
acclimated for 5 days prior to study initiation. All animals were housed in
pairs in individually vented cages mounted on a rack with positive airflow.
The room environment was maintained at 20°C to 21°C with a 12-h lightdark cycle. Prior to the start of the study, all rats received a standard rat
chow and autoclaved, double-distilled water ad libitum during the 5-day
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acclimation period. All animal procedures were approved by University of
Nebraska—Lincoln IACUC.
Rats were randomly assigned to one of five treatments, with three to six
rats per group. Groups 1 through 4 were fed a high-fat diet (60% kcal from
fat) (AIN-58G9 TestDiet) (see Table S1 in the supplemental material),
while group 5 received a standard diet (12% fat) (AIN-58G7 TestDiet) for
8 weeks. After 4 weeks of feeding, groups were assigned to one of the
following supplement treatments. Rats in groups 1 and 5 received no
additional treatment. Group 2 rats received drinking water supplemented
with 3.3% GOS to give ⬃1 g of GOS day⫺1 rat⫺1. Group 3 rats were given
drinking water supplemented with ⬃1 ⫻ 109 CFU of B. adolescentis IVS-1
day⫺1 rat⫺1. Group 4 rats received both the GOS and IVS-1 (synbiotic
mixture), at the same doses as those given to groups 2 and 3. All treatments were prepared fresh daily and administered for 4 weeks. The daily
water intake per rat was significantly different among groups and was used
to calculate the absolute doses of probiotic cells per day (P ⫽ 0.001) (see
Table S2 in the supplemental material). Rats fed the probiotic drank significantly more water (41.9 ⫾ 8.6 ml) than did rats fed the synbiotic
(35.4 ⫾ 4.5 ml), resulting in a significantly higher dose of IVS-1 in the
probiotic group (1.26 ⫻ 109 CFU versus 1.06 ⫻ 109 CFU; P ⫽ 0.0001).
GOS consumption was not significantly different between the prebioticand synbiotic-fed groups (P ⫽ 0.2063) (see Table S2 in the supplemental
material).
Body weights were determined weekly throughout the study. All rats
were necropsied after 8 weeks of study. Blood, cecum, colon content, liver,
and epididymal fat pads were collected, and the cecum and colon content
were immediately frozen in liquid nitrogen and stored at ⫺80°C until
further use.
Evaluation of host physiological parameters in rats. Liver lipid extraction was performed according to methods described previously by
Folch and colleagues (29). Aliquots of lipid extract were saponified to
quantify triglycerides (TGs) by using the TG diagnostic kit (Thermo dimethyl adipimidate kit; Thermo Electron Clinical Chemistry, Louisville,
CO). Data are reported as g TG mg⫺1 (wet weight) liver tissue. To
evaluate liver damage, plasma alanine aminotransferase (ALT) and alkaline phosphatase (ALP) enzyme levels were measured, which are indicators of hepatocyte damage/leakage and cholangiocyte stress, respectively
(30, 31). Blood was collected into heparinized tubes at necropsy, and ALT
and ALP levels were quantified by using a Mammalian Liver Profile rotor
in a VetScan VS2 analyzer (Abaxis, Union City, CA). Levels of tumor
necrosis factor alpha (TNF-␣) and monocyte chemoattractant protein 1
(MCP-1) were quantified as measures of systemic inflammation by using
a Milliplex rat magnetic bead multiplex assay (Merck Millipore, Billerica,
MA) according to the manufacturer’s protocol.
Illumina 16S RNA sequencing and sequence analysis. Colonic and
cecal contents were flash-frozen in liquid nitrogen at necropsy, and DNA
was extracted as described previously (26), with one modification: the
lysis buffer contained 20 mM Tris-HCl (pH 8), 2 mM EDTA, 1.2% Triton
X-100 (pH 8.0), and 20 mg ml⫺1 Lysozyme (MP Biomedicals, Solon,
OH). Amplicon sequencing of colonic contents was performed by the
University of Minnesota Genomics Center, and all samples were sequenced together in the same run. First, the V5-V6 region of the 16S rRNA
gene was amplified with primer pair 784F (5=-RGGATTAGATACCC-3=)
and 1064R (5=-CGACRRCCATGCANCACCT-3=) in a 25-l PCR mixture containing 5 l of template DNA, 5 l of 2⫻ HotStarTaq PCR master
mix, a final concentration of primers of 500 nM, and 0.025 U l⫺1 HotStarTaq polymerase (Qiagen Inc.). Amplification reactions included an
initial denaturation step at 95°C for 5 min followed by 20 to 25 cycles of
denaturation (50 s at 94°C), annealing (30 s at 40°C), and elongation (30
s at 72°C). Next, samples were diluted 1:100 in water for input into library
tailing PCR. The PCR was analogous to the one conducted for initial
amplification except for a Taq polymerase concentration of 0.25 U l⫺1,
and the PCR conditions consisted of an initial denaturation step at 95°C
for 5 min followed by 10 to 15 cycles of denaturation (50 s at 94°C),
annealing (30 s at 40°C), and elongation (1 min at 72°C).
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PCR products were quantified by using the Quant-iT PicoGreen double-stranded DNA (dsDNA) assay kit (Life Technologies). A subset of the
amplicon libraries was spot checked on a Bioanalyzer High-Sensitivity
DNA chip (Agilent Technologies, Santa Clara, CA) for correct amplicon
size. Next, samples were normalized to 2 nM and pooled. The total volume of the libraries was reduced by the use of a SpeedVac, and amplicons
were size selected at 420 bp ⫾ 20% by using the Caliper XT system
(PerkinElmer, Waltham, MA). Afterwards, library pools were cleaned
with 1.8⫻ AMPureXP beads (Beckman Coulter, Brea, CA) and eluted in
water. The amount of DNA in the final pool was quantified with PicoGreen
and normalized to 2 nM for input into the Illumina MiSeq platform (v3
kit) to produce 300-bp paired-end sequencing products. Clustering was
done at 10 pM with a 5% spike of PhiX. The generated sequences were
quality filtered with Illumina software at the University of Minnesota
Genomics Center. Twenty-two of 24 samples met all quality control criteria and were used for the microbial community analysis.
Microbial community analysis. Reads were trimmed to 240 bp with
the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/), and pairedend reads were merged with the merge-illumina-pairs application (https:
//github.com/meren/illumina-utils/) (P value of 0.03, enforced Q30
check, perfect matching to primers, and no ambiguous nucleotides allowed). Files exceeding 30,000 reads were subsampled to this number in
Mothur v.1.31.162 to standardize the sequencing depth across samples.
Subsequently, USEARCH v7.0.100163 was used to generate operational
taxonomic units (OTUs) with a 98% similarity cutoff. OTU generation
included the removal of putative chimeras identified against the Gold
reference database, in addition to the chimera removal inherent to the
OTU clustering step in UPARSE. After quality control and chimera removal, samples contained an average of 25,718 ⫾ 941 sequences. The
resulting sequences were also taxonomically characterized from phylum
to genus levels with Ribosomal Database Project (RDP) Classifier with the
MultiClassifier v1.1 tool. All phylotypes were computed as percent proportions based on the total number of sequences in each sample.
Statistical analysis. Results are expressed as means ⫾ standard deviations (SD) unless otherwise stated. To analyze bacterial composition,
diversity differences, and host physiological parameters, one-way analyses
of variance (ANOVA) with repeated measures in combination with
Tukey’s post hoc tests were applied. To achieve normality for data that
were not normally distributed, values were subjected to log10 transformations. If only two groups were compared, Student’s t tests were performed.
Spearman’s correlations were used to assess correlations between bacterial
groups. To account for type I errors, the false discovery rate was used. A P
value of ⬍0.05 and correlation coefficient (r) values of ⬎0.60 (in absolute
values) were considered significant. Analyses of variance and false discovery rate control were performed by using SAS/STAT (SAS Institute Inc.,
Cary, NC, USA), while correlations were determined by using GraphPad
Prism version 5.0 (GraphPad Software, La Jolla, CA, USA).
Nucleotide sequence accession number. The genome sequence of B.
adolescentis IVS-1 has been deposited in the DDBJ/EMBL/GenBank database under accession number JRNZ01000000.

RESULTS

In vivo selection of B. adolescentis IVS-1. In a previous study (25,
32), we reported a significant and remarkably specific enrichment
of Bifidobacterium populations in human subjects during dietary
supplementation with GOS (as demonstrated by 454 sequencing,
genus-specific qRT-PCR, and quantitative culture), which is in
agreement with data from other GOS feeding studies (33–38).
Cultural enumeration of fecal samples during the human trial
allowed us to identify individuals in which bifidobacteria were
enriched by GOS and from whom strains likely to utilize GOS in
vivo could be selected. This novel strategy for selection and recovery of autochthonous strains enriched by a prebiotic is referred to
as in vivo selection (IVS) (Fig. 1A). Using the IVS approach, a total
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FIG 1 In vivo selection to identify putative probiotic strains to be used in synbiotic applications. (A) Concept of in vivo selection. (B) Proportion of fecal
bifidobacteria in a human individual consuming GOS (included in chews) in four increasing doses (0, 2.5, 5, and 10 g) during a human feeding trial (25), as
determined by 454 pyrosequencing of 16S rRNA tags. (C) Proportion of Bifidobacterium lineage species II in the same individual, as determined by pyrosequencing. (D) Cell numbers of B. adolescentis IVS-1 in the same individual, as quantified by strain-specific qRT-PCR.

of 28 presumptive bifidobacterial colonies from 11 subjects were
isolated and classified by sequencing of the 16S rRNA genes. Eight
isolates were classified as Bifidobacterium adolescentis, eight were
classified as Bifidobacterium longum, three were classified as Bifidobacterium pseudocatenulatum, and one was classified as Bifidobacterium bifidum. Of the remaining isolates, four belonged to the
Coriobacterium genus, one could be classified only to the family
level (Lachnospiraceae), and three could not be sequenced due to
insufficient growth. All strains resulting in pure cultures were also
screened for their ability to ferment GOS during in vitro growth,
and 13 were classified as GOS fermenters, 12 were classified as
nonfermenters, and 3 could not be propagated to be tested (data
not shown). Out of the 13 strains able to ferment GOS, 5 were
classified as B. longum, 5 were classified as B. adolescentis, 1 was
classified as B. bifidum, 1 was classified as B. pseudocatenulatum,
and another one was classified as Lachnospiraceae. None of the
isolated Coriobacterium strains were classified as fermenters.
Based on the culture data, 454 sequencing (32), and the GOS
fermentation tests, we selected one strain and designated it IVS-1.
This strain originated from a subject who showed a strong bifidogenic response to GOS (Fig. 1B). Based on 16S rRNA sequencing,
IVS-1 had 98.4% identity (100% query coverage and an E value of
zero) with the 16S rRNA gene of B. adolescentis ATCC 15703T and
was therefore allotted to this species. However, the strain belongs
to a distinct phylogenetic cluster (Bifidobacterium species II cluster) detectable by using the V1-V3 region of the 16S rRNA gene
(32). This cluster was significantly enriched by GOS in all subjects,
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including the individual from whom IVS-1 was isolated (Fig. 1C).
The ability of B. adolescentis IVS-1 to utilize GOS was demonstrated by growth in MRS broth containing 2% GOS (see Fig. S1 in
the supplemental material). The established metabolic benefits of
the species B. adolescentis serve as another rationale for the selection of IVS-1 for future applications (39, 40).
To verify that B. adolescentis strain IVS-1 was specifically enriched by GOS in vivo, we devised a strain-specific qRT-PCR approach with primers based on the genome sequence of IVS-1.
Primer specificity was validated against 10 closely related Bifidobacterium strains, fecal DNA from all subjects included in the
human feeding trial (25) and five additional human individuals,
and 10 fecal samples from Sprague-Dawley rats from an independent experiment. A detectable PCR product was obtained only
with DNA from B. adolescentis IVS-1 and the fecal sample from
which the strain was isolated. This finding indicated that the primers were highly strain specific and that strain IVS-1 was present
only in the human subject from whom it was isolated.
The strain-specific qRT-PCR system was then used to quantify
the abundance of IVS-1 in fecal samples from this subject during
the GOS feeding study. This analysis revealed that IVS-1 levels
were increased 8-fold during both the 5-g and 10-g GOS dose
periods compared to the 0-g period (P ⬍ 0.001) (Fig. 1D), before
returning to baseline levels immediately after GOS consumption
ended. Collectively, these results demonstrated the utility of IVS
to select a bacterial strain enriched in the human gastrointestinal
tract through dietary administration of a prebiotic.
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FIG 2 Test of a synbiotic combination of B. adolescentis IVS-1 and GOS in a high-fat-diet rat model. (A) Experimental design of the rat study. Rats were fed either
a standard diet or a high-fat diet for 8 weeks, supplemented with or without a probiotic (IVS-1), a prebiotic (GOS), or a synbiotic (IVS-1 plus GOS) for the last
4 weeks. (B) Quantification of absolute cell numbers of bifidobacteria in colonic and cecal contents by genus-specific qRT-PCR. (C) Strain-specific qRT-PCR was
used to quantify absolute numbers of B. adolescentis IVS-1 in colonic and cecal contents.

Test of the synbiotic combination using rats on a high-fat
diet. We systematically tested synergism between strain IVS-1 and
GOS when used as a synbiotic in rats fed a high-fat diet (Fig. 2A).
Decreases in numbers of bifidobacteria are often observed during
high-fat-diet feeding (41–43). To determine if our synbiotic strategy could redress this decrease, we employed a rat model of highfat-diet-induced NAFLD where rats develop steatosis (fatty liver)
but do not show an increase in body weight, develop liver inflammation, or progress to nonalcoholic steatohepatitis (NASH) (28).
In our study, all high-fat-diet-fed rats developed steatosis (i.e.,
liver triglyceride levels of ⬎50 g mg⫺1 of tissue) and had slightly
increased plasma ALP levels compared to rats fed a standard diet
(see Table S2 in the supplemental material). Dietary supplements
significantly influenced triglyceride liver contents; however, highfat-diet-fed rats did not develop the histopathological liver inflammation characteristic of NASH (data not shown) and did not
have increased plasma ALT levels (see Table S2 in the supplemental material). Plasma tumor necrosis factor alpha (TNF-␣) and
monocyte chemoattractant protein 1 (MCP-1) levels were not significantly elevated in the high-fat-fed rats compared to the controls (see Table S2 in the supplemental material), indicating a lack
of systemic inflammation. Together, these data indicated that all
rats receiving a high-fat diet developed NAFLD but not severe
inflammatory disease that would confound the evaluation of synbiotic synergy and gut microbial ecology.
Experiments in rats demonstrate strong synergism between
IVS-1 and GOS. To test the functionality of the prebiotic to support the establishment of B. adolescentis IVS-1 in the rat intestine,
rats fed a high-fat diet were administered either IVS-1 alone, GOS
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alone, or the synbiotic combination; all findings were compared to
results for the high-fat controls (Fig. 2A). Consistent with data from
previous studies (41, 42), high-fat feeding decreased the abundance of
bifidobacteria in both the colon and cecum of the rats, although this
reduction did not reach statistical significance (Fig. 2B and Table 1).
Genus-specific qRT-PCR analysis revealed that the prebiotic, but not
IVS-1, significantly increased the total number of bifidobacteria in
the cecum (Fig. 2B). These findings indicate that the introduction of
IVS-1 alone did not increase Bifidobacterium abundance above
baseline levels (⬃108 cells/g), whereas the prebiotic substrate was
able to support the resident population. Compared to IVS-1 and
GOS alone, the combination of the two dramatically increased the
total number of bifidobacteria in the cecum (P ⬍ 0.01 between
synbiotic and prebiotic treatments; P ⬍ 0.001 between synbiotic
and probiotic treatments) (Fig. 2B).
Strain-specific qRT-PCR analysis of B. adolescentis IVS-1
clearly demonstrated a synergistic effect of IVS-1 and GOS in the
colon and in the cecum. Even though rats receiving IVS-1 alone
consumed significantly more IVS-1 on a daily basis than did rats
given the synbiotic due to increased drinking water consumption
(P ⫽ 0.0001) (see Table S2 in the supplemental material), the
synbiotic led to an almost 2-log increase in the level of IVS-1 in the
colon and cecum (9.47 ⫾ 0.2 log10 cells g⫺1 and 9.43 ⫾ 0.2 log10
cells g⫺1, respectively) compared with the probiotic treatment
(7.9 ⫾ 0.1 and 7.44 ⫾ 0.3 log10 cells g⫺1 in the cecum and colon,
respectively) (P ⫽ 0.0001) (Fig. 2C). No IVS-1 was detected in rats
fed the standard diet, the high-fat diet, or the prebiotic alone.
16S rRNA sequencing confirms synergism between IVS-1
and GOS in vivo. We analyzed the 16S rRNA tags obtained via
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TABLE 1 Proportions of bacterial taxa significantly influenced by dietary treatments
Mean % bacterial abundance ⫾ SDc
Taxonomic group

Standard
diet

Control
HF diet

Prebiotic
(HF)

Probiotic
(HF)

Synbiotic
(HF)

P value
determined by
ANOVA

Phyla
Firmicutes
Actinobacteria

87.6 ⫾ 5 A
8.9 ⫾ 6 AB

88.8 ⫾ 9 A
3.6 ⫾ 2 A

76.9 ⫾ 8 A
19.6 ⫾ 8 BC

87.8 ⫾ 5 A
7.6 ⫾ 4 A

59.3 ⫾ 7 B
39.1 ⫾ 7 C

⬍0.0001
⬍0.0001

Families
Clostridiaceae
Incertae sedis XIV
Streptococcaceae
Erysipelotrichaceae
Bifidobacteriaceae
Coriobacteriaceae
Rikenellaceae

3.9 ⫾ 6
3.7 ⫾ 6
12.7 ⫾ 5
16.8 ⫾ 11
5.9 ⫾ 7 A
0.6 ⫾ 0
0.9 ⫾ 1 A

0.5 ⫾ 1
7.5 ⫾ 10
21.3 ⫾ 5 A
21.3 ⫾ 17
1.3 ⫾ 1 A
0.3 ⫾ 0
0.1 ⫾ 0

0.8 ⫾ 1
11.0 ⫾ 15
9.3 ⫾ 1
9.2 ⫾ 1 A
17.0 ⫾ 9
1.0 ⫾ 1
0.3 ⫾ 0

5.4 ⫾ 6 A
1.1 ⫾ 2 A
8.9 ⫾ 6 B
26.5 ⫾ 10 B
4.1 ⫾ 2 A
1.9 ⫾ 3 A
0.1 ⫾ 0

0.2 ⫾ 0 B
17.3 ⫾ 12 B
6.6 ⫾ 2 B
8.3 ⫾ 3 A
37.8 ⫾ 7 B
0.2 ⫾ 0 B
0.0 ⫾ 0 B

0.0061
0.0342
0.0045
0.0226
0.0017
0.0263
0.0181

Genera
Clostridium
Blautia
Holdemania
Bifidobacterium
Lactococcus
Alistipes

3.9 ⫾ 6
3.4 ⫾ 6
0.1 ⫾ 0
5.9 ⫾ 7 A
12.4 ⫾ 4
0.9 ⫾ 1 A

0.5 ⫾ 1 A
7.4 ⫾ 10
1.0 ⫾ 2 A
1.3 ⫾ 1 A
21.0 ⫾ 5 A
0.1 ⫾ 0

0.8 ⫾ 1
11.0 ⫾ 15
0.9 ⫾ 0
17.0 ⫾ 9
9.1 ⫾ 1
0.3 ⫾ 0

5.3 ⫾ 6 B
0.9 ⫾ 1 A
0.0 ⫾ 0 B
4.1 ⫾ 2 A
8.7 ⫾ 6 B
0.1 ⫾ 0

0.2 ⫾ 0 A
17.2 ⫾ 12 B
0.0 ⫾ 0 B
37.8 ⫾ 7 B
6.3 ⫾ 2 B
0.0 ⫾ 0 B

0.0122
0.0431
0.0117
0.0017
0.0045
0.0181

OTUsa
OTU_2 (B. adolescentis, 99%)
OTU_1 (L. lactis, 100%)
OTU_626 (Lachnospiraceaeb)
OTU_7 (Turicibacter sanguinis, 97%)
OTU_14 (Blautiab)
OTU_33 (L. intestinalis, 99%)
OTU_9 (Clostridium sp.b)
OTU_6 (B. pseudolongum, 97%)
OTU_44 (Clostridium cocleatum, 99%)

0.0 ⫾ 0 A
12.4 ⫾ 4
0.4 ⫾ 1 A
3.7 ⫾ 3
0.0 ⫾ 0 A
ND
3.8 ⫾ 6
5.8 ⫾ 7
ND

0.0 ⫾ 0 A
21.0 ⫾ 5 A
0.1 ⫾ 0 A
2.3 ⫾ 3
0.1 ⫾ 0 AB
0.0 ⫾ 0 A
0.5 ⫾ 1 A
0.9 ⫾ 1
1.0 ⫾ 1 A

0.0 ⫾ 0 A
9.1 ⫾ 1
0.0 ⫾ 0 B
2.3 ⫾ 2
1.5 ⫾ 1 BC
ND
0.7 ⫾ 1
16.6 ⫾ 8 A
ND

3.4 ⫾ 2 BC
8.6 ⫾ 6 B
ND
9.1 ⫾ 7 A
0.0 ⫾ 0 AB
1.1 ⫾ 2 B
5.3 ⫾ 6 B
0.6 ⫾ 1
0.0 ⫾ 0 B

37.0 ⫾ 7 BD
6.3 ⫾ 2 B
0.1 ⫾ 0
0.5 ⫾ 1 B
9.7 ⫾ 6 CD
0.0 ⫾ 0 A
0.2 ⫾ 0 A
0.0 ⫾ 0 B
ND

⬍0.0001
0.0045
0.0002
0.0279
0.0003
0.0022
0.0128
0.0293
0.0121

a

Percent homologies to the closest type strain in the database are shown in parentheses. If the strain could not be assigned to a type strain (⬍97% homology), RDP Classifier was
used to determine the most likely genus, and the RDP Classifier value is shown (80% cutoff).
b
OTU without closely related type strain (⬍97% homology) classified with RDP Classifier.
c
Values with different uppercase letters are significantly different from each other. HF, high fat; ND, not detected.

Illumina sequencing to gain a community-wide perspective on
treatment effects on the resident gut microbiota. The ability of
pro- and synbiotic treatments to establish IVS-1 in rats was assessed based on the abundance of an operational taxonomic unit
(OTU) representing the species B. adolescentis (OTU_2). This species was undetectable in rats that did not receive the probiotic
treatment but constituted 3.4% of the microbiota in rats fed IVS-1
(Fig. 3A and Table 1). This finding indicates that the B. adolescentis
population observed in rats was due solely to the administration of
IVS-1. This finding was expected, as this species is not a member of
the normal rat microbiota. Sequences representing B. adolescentis
were enriched to 37.0% in rats receiving the synbiotic treatment,
indicating a significant enhancement of the probiotic (in terms of
abundance) due to the addition of the prebiotic (P ⫽ 0.0159).
Without GOS, IVS-1 was only the eighth most abundant OTU in
the rats’ colonic microbiota, while it became the most abundant
OTU when given together with GOS, having an abundance almost
four times higher than that of the second most abundant OTU (a
Blautia species, at 9.7%) (Fig. 3A). This finding demonstrated that
IVS-1 could be introduced as the dominant member of the rat gut
microbiota when GOS was also provided.
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Community-wide characterization of effects on gut microbiota. GOS treatment alone promoted a remarkably specific bifidogenic response, leading to an increase in the abundance of only
one OTU related to Bifidobacterium pseudolongum (OTU_6) (Table 1 and Fig. 3A). These findings confirm the highly specific bifidogenic response of GOS, which was previously demonstrated in
humans (32).
Although IVS-1 treatment alone did not significantly increase
the abundance of the genus Bifidobacterium, it induced a significant increase in the abundance of Bifidobacterium adolescentis at
the species level (Table 1). Of note, several unexpected changes
were also detected, such as enrichment of the family Clostridiaceae, the genus Clostridium, and an OTU within this genus
(OTU_9). Furthermore, the abundance of an OTU related to Lactobacillus intestinalis (OTU_33) increased, while that of an OTU
related to Lactococcus lactis (OTU_1) decreased (Table 1).
Synbiotic treatment significantly increased the proportion of
Actinobacteria (P ⬍ 0.0001), the family Bifidobacteriaceae (P ⫽
0.0017), and the genus Bifidobacterium (P ⫽ 0.0017) (Table 1).
These shifts were almost completely equivalent to shifts of
OTU_2, showing that the above-described alterations at higher
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FIG 3 Characterization of the rat colonic microbiota composition by Illumina sequencing of 16S rRNA tags. (A) Analysis of colonic microbiota at the OTU level.
OTUs representing at least 1% of total sequences are shown individually, while OTUs representing ⬍1% are grouped. OTUs in colors other than light blue were
significantly influenced by the dietary treatment. (B) Principal coordinate analysis (Bray-Curtis distance) of beta diversity. (C) NMDS plot of beta diversity based
on Bray-Curtis distance. SD, standard diet.

taxonomic levels were due to the enrichment of IVS-1. The
establishment of IVS-1 was associated with an increase in the
abundances of the genus Blautia and one OTU within this genus
(OTU_14). In addition, there was a reduction in the abundances
of the phylum Firmicutes (P ⬍ 0.0001) and families within this
phylum, including Clostridiaceae, Streptococcaceae, and Erysipelotrichaceae. The abundances of the genera Clostridium and Lactococcus and OTUs within these genera were also decreased (Table 1).
To assess both the alpha and beta diversities of the community
in the colon, different diversity indexes were calculated from the
data. Specifically, Shannon’s index and the number of observed
OTUs were used to determine the alpha diversity, and principal
coordinate analysis (PCoA) and nonmetric multidimensional
scaling (NMDS) plots based on Bray-Curtis distance were used to
visualize the similarity between samples for each treatment.

April 2015 Volume 81 Number 7

On average, 135.41 ⫾ 34.4 OTUs per sample were identified.
Alpha diversity based on Shannon’s index was not significantly
influenced by the treatment; however, there was a tendency for
reduced diversity in the synbiotic group. This was caused by a
slight reduction in community evenness, likely due to the expansion of a single species (B. adolescentis) (data not shown). Two
independent approaches were used to analyze the beta diversity of
the microbiota communities among treatments. PCoA and
NMDS, based on Bray-Curtis distances of beta diversity, revealed
that communities from rats fed the synbiotic clustered separately
from the microbiomes of rats fed all the other treatments, which
clustered together (Fig. 3B and C). This finding demonstrated that
only the synbiotic treatment caused a global shift in microbiota
structure.
Systematic analyses of associations between members of the
gut microbiota. To identify potential interactions between IVS-1
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FIG 4 Correlation analysis of colonic taxa present in rats fed a high-fat diet supplemented with or without a probiotic (IVS-1), a prebiotic (GOS), or a synbiotic
(IVS-1 plus GOS) or a standard diet. Bacterial quantities are expressed as percent abundances of total bacteria as determined by 16S rRNA sequencing.
Spearman’s correlations between Bifidobacteriaceae and Clostridiaceae (A), Bifidobacterium and Lactococcus (B), Bifidobacterium and Akkermansia (C), Bifidobacterium adolescentis IVS-1 and Lactococcus lactis (D), Bifidobacterium adolescentis IVS-1 and Bifidobacterium pseudolongum (E), and Bifidobacterium and
Blautia (F) were determined.

and members of the gut microbiota, and among other bacterial
members, we performed correlation analyses on all taxon combinations in the data set. Correlations were performed by using bacterial abundance data from all treatments. Strong negative correlations between the family Bifidobacteriaceae and the family
Clostridiaceae (Fig. 4A), the genera Bifidobacterium and Lactococcus (Fig. 4B), and the genera Bifidobacterium and Akkermansia
(Fig. 4C) were observed. In addition, strain IVS-1 levels (OTU_2)
showed a negative correlation with Lactococcus lactis (Fig. 4D) and
a very tight negative association with resident B. pseudolongum
(r ⫽ ⫺0.64; P ⫽ 0.0004) (Fig. 4E). These negative associations
suggest direct or indirect competition between these bacterial
taxa. Positive associations between both Bifidobacteriaceae and Bifidobacterium and the genus Blautia were detected, suggesting a
synergistic relationship, which may be supported by the addition
of GOS (Table 1 and Fig. 4F).
DISCUSSION

Synergistic synbiotics are a promising concept to modulate the
composition of the gut microbiota and promote the establishment of probiotic organisms in the gut (16). Despite this potential, however, there are few in vivo human or animal studies
providing evidence that prebiotics can be used to support specific probiotic strains. Unfortunately, most synbiotic studies,
including work in rats (44–49), mice (50–52), pigs (53–57),
chickens (58, 59), and humans (60), did not employ strainspecific detection methods and therefore did not provide information on the potential synergism between pre- and probiotics. Of the in vivo studies that did discriminate the probiotic
strain, most still did not demonstrate that in vivo performance
could be enhanced by a prebiotic. This accounts for experiments using synbiotic formulations in humans (61), rats (62,
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63), and other animal models (64). These findings suggest that,
with few exceptions (17–19), probiotic strains are unable to
compete against the resident gut microbiota, which is inherently resistant to outside colonizers (65), even when an exogenous growth substrate in the form of a prebiotic is provided.
Several reasons may explain the low success rates of synergistic synbiotics when evaluated in vivo, even for combinations
in which the probiotic strain is able to utilize the prebiotic
substrate in vitro. First, to become established in the gut, the
probiotic strain must be able to occupy an ecological niche.
This means that strains must not only outcompete the resident
microbiota for the prebiotic substrate but also secure other
nutrients that might be growth limiting (such as amino acids,
lipids, vitamins, minerals, and nucleotides, etc.). In addition,
probiotic strains must tolerate the prevailing environmental
conditions in the digestive tract (including pH, bile acids, IgA,
and defensins). Ultimately, in vitro tests are unable to predict
the ability of a probiotic to benefit from a prebiotic substrate
within the constraints of the competitive gastrointestinal environment. In contrast, the IVS approach described here overcomes many limitations of in vitro tests used to formulate synbiotics because it provides a basis for identifying bacterial
strains that are able to utilize the prebiotic substrate under the
same ecological conditions in which they are intended to function.
In this study, we employed IVS and selected a synbiotic combination that was tested in a rat model of NAFLD. Although the
synbiotic did not influence host phenotypes, it was highly efficient
at enhancing population levels of the probiotic strain, making it
the most dominant OTU in the gut (Fig. 3A and Table 1). These
findings provide a proof of concept for the potential of in vivo
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selection to identify synbiotic combinations that are, in ecological
terms, highly synergistic. In addition to enhancing the abundance
of strain IVS-1, the synbiotic used here also redressed the high-fatdiet-induced reduction in the level of bifidobacteria detected in
rats that is often reported in the literature (41–43). Therefore,
although no metabolic benefits were seen in the rat model used in
our study, the synbiotic may be beneficial in other scenarios, as
bifidobacteria are considered health-promoting organisms (6, 26,
66–68).
The community-wide analysis provided evidence that synergism between GOS and strain IVS-1 increased the competitive
fitness of the strain in the rat intestinal tract. B. pseudolongum,
which is a natural member of the rat GI tract (69), was detected in
relative abundances of 5.8% and 0.9% in rats fed the standard and
high-fat diets, respectively. Although the probiotic treatment did
not affect levels of B. pseudolongum, the prebiotic treatment increased the abundance of this species to 16.6%, indicating that B.
pseudolongum utilized GOS in vivo. However, the parallel addition
of strain IVS-1 with GOS completely excluded B. pseudolongum,
and a strong negative correlation between this species and IVS-1
was observed (r ⫽ ⫺0.67; P ⫽ 0.0006) (Fig. 4E). These findings
indicate that IVS-1 not only had a higher affinity for GOS in vivo
than the resident Bifidobacterium species but also utilized GOS to
increase its competitiveness and effectively outcompete a closely
related resident species. This finding is consistent with the niche
exclusion model, which states that the organism most efficient at
using limited nutrients outcompetes its competitors for the same
niche (70). Strong inverse correlations between bifidobacteria and
Clostridiaceae, Lactococcus, and Akkermansia (Fig. 4A to C) were
also observed. It is likely that these associations are also due to
niche competition and are potentially enhanced by GOS administration. Bifidobacteria produce short-chain fatty acids that are
inhibitory to other bacteria either by lowering the pH or via direct
antimicrobial effects (e.g., acetic acid) (71). In summary, these
findings demonstrate that the competitive fitness of strain IVS-1
was increased by GOS, which supports the conclusion that IVS can
select synbiotic combinations with extremely high synergism. To
what degree the increased competitive interactions between IVS-1
and the resident microbiota impact host health is difficult to predict and likely context dependent, but they clearly should be considered in future studies.
Correlation analyses revealed only one positive association
among members of the rat microbiota, between the bifidobacteria
(at the family and genus levels) and the genus Blautia. The abundance of OTU_14, an uncultured Blautia strain, was also significantly increased by GOS and in the synbiotic treatment (Table 1).
The positive correlation between Bifidobacterium and Blautia
(Fig. 4F) indicates a synergistic effect between the two taxa. The
significant increase in the abundance of Blautia in the synbiotic
treatments further suggests a syntrophic interaction between
IVS-1 and Blautia, as GOS is consumed mainly by bifidobacteria
(72), and the genus Blautia is not reported to utilize GOS. In
contrast, the genus Blautia contains bacteria that are hydrogenotrophic acetogens, which utilize H2 and CO2 as energy
sources (73). Although bifidobacteria do not produce these gases,
cross-feeding between bifidobacteria and butyrate-producing colon bacteria can result in H2 and CO2 production (74), which
might explain the positive correlations between Bifidobacterium
and Blautia. However, additional experiments are necessary to
establish the mechanism by which GOS can enhance the popula-
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tions of Blautia in the gut and the positive associations between
this genus and IVS-1.
In this study, we have shown how IVS can be used to formulate
a highly synergistic synbiotic that can substantially enhance population levels and the competitiveness of a putative probiotic
strain in the gastrointestinal tract and establish it as the dominant
member of the gut microbiota in a conventional animal model. To
our knowledge, this has not yet been reported in the probiotic
literature. The process of IVS is broadly applicable and can easily
be extended to other host species, body sites, prebiotic substrates
(or dietary fibers), or target organisms. For example, it may be
possible to use IVS to enhance other putative health-promoting
genera such as Akkermansia, which has been shown to respond to
prebiotics in vivo (75). While we selected B. adolescentis IVS-1
during a human trial that did not determine the physiological
effect of GOS, IVS might be especially powerful when combined
with a human clinical trial that determines the beneficial effect of
a prebiotic on the host as the primary selection criterion. Therefore, to develop synbiotics for specific health applications, the IVS
concept should be extended to select bacterial strains that not only
responded to the prebiotic but whose expansion correlated with
beneficial physiological effects for the host. Such an approach
would have the potential to identify health-promoting strains
whose metabolic activity in vivo could be increased through a prebiotic. This might also result in synbiotic applications with greater
health effects than those of the prebiotic alone, especially in the
subset of humans who do not respond to the prebiotic (14, 32). A
human study testing the synbiotic combination identified here
(and comparing it with a synbiotic that includes a Bifidobacterium
strain that can ferment GOS but was not selected by IVS) is currently in progress. Clearly, the application of IVS is likely to enhance the ecological performance of probiotic strains or live biotherapeutics within the habitats in which they are thought to
function, and the technology could be readily applied in the design
of microbiota-modulating therapies.
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Z, Klimešová K, Přibylová J, Bártová J, Sanchez D, Fundová P, Borovská D, Srùtková D, Zídek Z, Schwarzer M, Drastich P, Funda DP.
2011. The role of gut microbiota (commensal bacteria) and the mucosal
barrier in the pathogenesis of inflammatory and autoimmune diseases and
cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 8:110 –120. http://dx.doi.org/10.1038
/cmi.2010.67.
Cani PD, Delzenne NM. 2009. Interplay between obesity and associated
metabolic disorders: new insights into the gut microbiota. Curr Opin
Pharmacol 9:737–743. http://dx.doi.org/10.1016/j.coph.2009.06.016.
Hooper LV, Littman DR, Macpherson AJ. 2012. Interactions between
the microbiota and the immune system. Science 336:1268 –1273. http://dx
.doi.org/10.1126/science.1223490.
Walker AW, Lawley TD. 2013. Therapeutic modulation of intestinal
dysbiosis. Pharmacol Res 69:75– 86. http://dx.doi.org/10.1016/j.phrs
.2012.09.008.
Frank DN, Pace NR. 2008. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol 24:4 –10. http://dx.doi.org/10
.1097/MOG.0b013e3282f2b0e8.
Al-Sheraji SH, Ismail A, Manap MY, Mustafa S, Yusof RM, Hassan FA.
2013. Prebiotics as functional foods: a review. J Funct Foods 5:1542–1553.
http://dx.doi.org/10.1016/j.jff.2013.08.009.
Gibson GR, Roberfroid MB. 1995. Dietary modulation of the human
colonic microbiota: introducing the concept of prebiotics. J Nutr 125:
1401–1412.
Tuohy KM, Probert HM, Smejkal CW, Gibson GR. 2003. Using probiotics and prebiotics to improve gut health. Drug Discov Today 8:692–700.
http://dx.doi.org/10.1016/S1359-6446(03)02746-6.
Hooda S, Boler BMV, Serao MCR, Brulc JM, Staeger MA, Boileau TW,
Dowd SE, Fahey GC, Jr, Swanson KS. 2012. 454 pyrosequencing reveals
a shift in fecal microbiota of healthy adult men consuming polydextrose or
soluble corn fiber. J Nutr 142:1259 –1265. http://dx.doi.org/10.3945/jn
.112.158766.
Martínez I, Kim J, Duffy PR, Schlegel VL, Walter J. 2010. Resistant
starches types 2 and 4 have differential effects on the composition of the
fecal microbiota in human subjects. PLoS One 5:e15046. http://dx.doi.org
/10.1371/journal.pone.0015046.
Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli
L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. 2014.
Expert consensus document: the International Scientific Association for
Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506 –514.
http://dx.doi.org/10.1038/nrgastro.2014.66.
Kolida S, Gibson GR. 2011. Synbiotics in health and disease. Annu Rev
Food Sci Technol 2:373–393. http://dx.doi.org/10.1146/annurev-food
-022510-133739.
Tanaka R, Takayama H, Morotomi M, Kuroshima T, Ueyama S, Matsumoto K, Kuroda A, Masahiko M. 1983. Effects of administration of
TOS and Bifidobacterium breve 4006 on the human fecal flora. Bifidobact
Microflora 2:17–24. http://dx.doi.org/10.12938/bifidus1982.2.1_17.
Ogawa T, Asai Y, Yasuda K, Sakamoto H. 2005. Oral immunoadjuvant
activity of a new synbiotic Lactobacillus casei subsp casei in conjunction
with dextran in BALB/c mice. Nutr Res 25:295–304. http://dx.doi.org/10
.1016/j.nutres.2004.10.012.
Ogawa T, Asai Y, Tamai R, Makimura Y, Sakamoto H, Hashikawa S,
Yasuda K. 2006. Natural killer cell activities of synbiotic Lactobacillus
casei ssp. casei in conjunction with dextran. Clin Exp Immunol 143:103–
109. http://dx.doi.org/10.1111/j.1365-2249.2005.02975.x.
Rabiu BA, Jay AJ, Gibson GR, Rastall RA. 2001. Synthesis and fermentation properties of novel galacto-oligosaccharides by beta-galactosidases
from Bifidobacterium species. Appl Environ Microbiol 67:2526 –2530.
http://dx.doi.org/10.1128/AEM.67.6.2526-2530.2001.
Modesto M, D’Aimmo MR, Stefanini I, Trevisi P, De Filippi S, Casini
L, Mazzoni M, Bosi P, Biavati B. 2009. A novel strategy to select Bifidobacterium strains and prebiotics as natural growth promoters in newly
weaned pigs. Livest Sci 122:248 –258. http://dx.doi.org/10.1016/j.livsci
.2008.08.017.
Malinen E, Mättö J, Salmitie M, Alander M, Saarela M, Palva A. 2002.
Analysis of Bifidobacterium populations in human faecal samples from a
consumption trial with Bifidobacterium lactis Bb-12 and a galactooligosaccharide preparation. Syst Appl Microbiol 25:249 –258. http://dx
.doi.org/10.1078/0723-2020-00117.

2464

aem.asm.org

23. Alander M, Mättö J, Kneifel W, Johansson M, Koegle B, Crittenden R,
Mattila-Sandholm T, Saarela M. 2001. Effect of galacto-oligosaccharide
supplementation on human faecal microflora and on survival and persistence of Bifidobacterium lactis Bb-12 in the gastrointestinal tract. Int
Dairy J 11:817– 825. http://dx.doi.org/10.1016/S0958-6946(01)00100-5.
24. Rattanaprasert M, Roos S, Hutkins RW, Walter J. 2014. Quantitative
evaluation of synbiotic strategies to improve persistence and metabolic
activity of Lactobacillus reuteri DSM 17938 in the human gastrointestinal
tract. J Funct Foods 10:85–94. http://dx.doi.org/10.1016/j.jff.2014.05.017.
25. Davis LMG, Martínez I, Walter J, Hutkins R. 2010. A dose dependent
impact of prebiotic galactooligosaccharides on the intestinal microbiota of
healthy adults. Int J Food Microbiol 144:285–292. http://dx.doi.org/10
.1016/j.ijfoodmicro.2010.10.007.
26. Martínez I, Wallace G, Zhang C, Legge R, Benson AK, Carr TP,
Moriyama EN, Walter J. 2009. Diet-induced metabolic improvements in
a hamster model of hypercholesterolemia are strongly linked to alterations
of the gut microbiota. Appl Environ Microbiol 75:4175– 4184. http://dx
.doi.org/10.1128/AEM.00380-09.
27. Rozen S, Skaletsky H. 2000. Primer3 on the WWW for general users and
for biologist programmers. Methods Mol Biol 132:365–386.
28. Ahmed U, Redgrave TG, Oates PS. 2009. Effect of dietary fat to produce
non-alcoholic fatty liver in the rat. J Gastroenterol Hepatol 24:1463–1471.
http://dx.doi.org/10.1111/j.1440-1746.2009.05870.x.
29. Folch J, Lees M, Sloan Stanely G. 1957. A simple method for the isolation
and purification of total lipids from animal tissues. J Biol Chem 226:497–
509.
30. Simental-Mendía LE, Rodríguez-Hernández H, Rodríguez-Morán M,
Guerrero-Romero F. 2012. The alanine aminotransferase to triglycerides
ratio as a marker to identify nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 24:1173–1177. http://dx.doi.org/10.1097/MEG.0b013e32
83564ee5.
31. Lee J-T, Pao L-H, Lee M-S, Liao J-W, Shih C-M, Hsiong C-H, Yin F-Y,
Shih T-Y, Hu OY-P. 2013. A new approach to facilitate diagnosis of
nonalcoholic fatty liver disease through a galactose single point method in
rats with fatty liver. Dig Liver Dis 45:134 –141. http://dx.doi.org/10.1016
/j.dld.2012.08.019.
32. Davis LMG, Martínez I, Walter J, Goin C, Hutkins RW. 2011. Barcoded
pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. PLoS One
6:e25200. http://dx.doi.org/10.1371/journal.pone.0025200.
33. Ito M, Deguchi Y, Miyamori A, Matsumoto K, Kikuchi H, Kobayashi Y,
Yajima T, Kan T. 1990. Effects of administration of galactooligosaccharides on the human faecal microflora, stool weight and abdominal sensation. Microb Ecol Health Dis 3:285–292. http://dx.doi.org/10.3109
/08910609009140251.
34. Gibson GR. 1999. Dietary modulation of the human gut microflora using
the prebiotics oligofructose and inulin. J Nutr 129:1438 –1441.
35. Sako T, Matsumoto K, Tanaka R. 1999. Recent progress on research and
applications of non-digestible galacto-oligosaccharides. Int Dairy J 9:69 –
80. http://dx.doi.org/10.1016/S0958-6946(99)00046-1.
36. Macfarlane S, Macfarlane GT, Cummings JH. 2006. Review article:
prebiotics in the gastrointestinal tract. Aliment Pharmacol Ther 24:701–
714. http://dx.doi.org/10.1111/j.1365-2036.2006.03042.x.
37. Silk DBA, Davis A, Vulevic J, Tzortzis G, Gibson GR. 2009. Clinical trial:
the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota
and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 29:
508 –518. http://dx.doi.org/10.1111/j.1365-2036.2008.03911.x.
38. Ben X-M. 2008. Low level of galacto-oligosaccharide in infant formula
stimulates growth of intestinal Bifidobacteria and Lactobacilli. World J
Gastroenterol 14:6564 – 6568. http://dx.doi.org/10.3748/wjg.14.6564.
39. Chen J, Wang R, Li X-F, Wang R-L. 2012. Bifidobacterium adolescentis
supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. Br J Nutr
107:1429 –1434. http://dx.doi.org/10.1017/S0007114511004491.
40. Reichold A, Brenner SA, Spruss A, Förster-Fromme K, Bergheim I,
Bischoff SC. 2014. Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model. J Nutr Biochem
25:118 –125. http://dx.doi.org/10.1016/j.jnutbio.2013.09.011.
41. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM,
Gibson GR, Delzenne NM. 2007. Selective increases of bifidobacteria in
gut microflora improve high-fat-diet-induced diabetes in mice through a
mechanism associated with endotoxaemia. Diabetologia 50:2374 –2383.
http://dx.doi.org/10.1007/s00125-007-0791-0.

Applied and Environmental Microbiology

April 2015 Volume 81 Number 7

In Vivo Selection of a Synergistic Synbiotic

42. Everard A, Lazarevic V, Gaïa N, Johansson M, Ståhlman M, Backhed F,
Delzenne NM, Schrenzel J, François P, Cani PD. 2014. Microbiome of
prebiotic-treated mice reveals novel targets involved in host response during
obesity. ISME J 8:2116 –2130. http://dx.doi.org/10.1038/ismej.2014.45.
43. Cani PD, Delzenne NM, Amar J, Burcelin R. 2008. Role of gut microflora in the development of obesity and insulin resistance following highfat diet feeding. Pathol Biol 56:305–309. http://dx.doi.org/10.1016/j
.patbio.2007.09.008.
44. Liong MT, Shah NP. 2006. Effects of a Lactobacillus casei synbiotic on serum
lipoprotein, intestinal microflora, and organic acids in rats. J Dairy Sci 89:
1390 –1399. http://dx.doi.org/10.3168/jds.S0022-0302(06)72207-X.
45. Yang S-C, Chen J-Y, Shang H-F, Cheng T-Y, Tsou SC, Chen J-R. 2005.
Effect of synbiotics on intestinal microflora and digestive enzyme activities
in rats. World J Gastroenterol 11:7413–7417. http://dx.doi.org/10.3748
/wjg.v11.i47.7413.
46. Le Leu RK, Brown IL, Hu Y, Bird AR, Jackson M, Esterman A, Young
GP. 2005. A synbiotic combination of resistant starch and Bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat
colon. J Nutr 135:996 –1001.
47. Igarashi M, Liyama Y, Kato R, Tomita M, Asami N. 1994. Effect of
Bifidobacterium longum and lactulose on the strength of bone in ovariectomized osteoporosis model rats. Bifidus 7:139 –147.
48. Bielecka M, Biedrzycka E, Majkowska A. 2002. Selection of probiotics
and prebiotics for synbiotics and confirmation of their in vivo effectiveness. Food Res Int 35:125–131. http://dx.doi.org/10.1016/S0963-9969
(01)00173-9.
49. Bomhof MR, Saha DC, Reid DT, Paul HA, Reimer RA. 2014. Combined
effects of oligofructose and Bifidobacterium animalis on gut microbiota
and glycemia in obese rats. Obesity 22:763–771. http://dx.doi.org/10.1002
/oby.20632.
50. Frece J, Kos B, Svetec IK, Zgaga Z, Beganović J, Lebos A, Susković J.
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Table S1. Composition of standard and high-fat diets.
Nutritional profile

High-Fat Diet

Standard Diet

Protein [%]

24.2

17.6

Fat [%]

34.7

5.2

Fiber (max) [%]

5.5

3.9

Carbohydrates [%]

27.8

68.3

Energy (kcal/g)

Kcal / %

Kcal / %

From Protein

0.969 / 18.6

0.705 / 18.3

From Fat (ether extract)

3.122 / 59.9

0.464 / 12.1

From Carbohydrates

1.113 / 21.4

2.733 / 71.0

Table S2. Body weight, relative epididymal fat pad weight, consumed drinking water,
consumed IVS-1 and GOS, and host physiological markers.
Standard
Diet

High-Fat
Diet

High-Fat Diet
Prebiotic

High-Fat Diet
Probiotic

High-Fat
Diet
Synbiotic

p - value
ANOVA

Average body
-1
weight [g rat ]

475 ±19

449 ±46

499 ±81

496 ±62

502 ±51

0.5446

Average relative
epididymal fat pad
-1
weight [% rat ]

0.84 ±0.2

1.04 ±0.4

1.12 ±0.3

1.01 ±0.2

1.08 ±0.5

0.8267

Average water
consumption [ml
-1
-1
rat day ]

29.3 ±4.1

b

35.6 ±4.5

a

36.3 ±4.9

a

41.9 ±8.6

c

35.4 ±4.5

Average IVS-1
consumption [CFU
-1
-1
rat day ]

NA

NA

NA

Average GOS
-1
consumption [g rat
-1
day ]

NA

NA

1.20

Triglyceride content
-1
[µg TG mg tissue]

17.8 ±4.3

Alkanine
Phosphatase (ALP)
-1
[units liter ]

227 ±83

399 ±55

Alanine
Transferase (ALT)
-1
[units liter ]

34 ±13

a

b

9a

1.26 x 10

NA

<0.0001

9b

0.0001

1.06 x 10

#

#

1.17

0.2063

53.5 ±0.8

c

92.4 ±2.4

464 ±127

458 ±167

460 ±120

0.0646

42 ±11

36 ±5

37±7

41 ±4

0.6418

14.2 ±2.3

14.1 ±2.6

16.2 ±3.2

16.7 ±7.9

13.8 ±1.4

0.4718

224 ±25

228 ±37

239 ±21

248 ±63

243 ±36

0.6345

70.7 ±1.4

bc

a

62.7 ±1.2

d

<0.0001

*

-1

TNF-α [pg ml ]

-1

MCP-1 [pg ml ]

*

as a threshold for steatosis was a liver triglyceride levels greater than 50 µg/mg of tissue
NA: not applicable
#
Student’s t-test was applied
Values with different letters are significantly different from each other

Figure S1. Growth of B. adolescentis IVS-1 in basal MRS supplemented with GOS,
0.16% lactose (residual sugar present in the commercial GOS), or basal MRS without
carbohydrates.

